Multideoxy Or Didehydro Patents (Class 536/28.2)
  • Protonated/acidified nucleic acids and methods of use
    Patent number: 6211349
    Abstract: The novel discovery that protonated nucleic acids inhibit bacterial growth is reported and methods for the preparation and therapeutic use of nuclease resistant and acid resistant protonated/acidified nucleic acids for administration to animals including man, to treat or prevent a bacterial infection are described.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: April 3, 2001
    Assignee: Oligos Etc., Inc.
    Inventors: Roderic M. K. Dale, Amy Arrow, Steven L. Gatton, Terry Thompson
  • Antiviral, highly water soluble, stable, crystalline salts of 2?, 3?-dideoxyinosine, 2?, 3?-dideoxy-2?, 3?-didehydrothymidine and 2?, 3?-dideoxy-2?-fluoroinosine
    Patent number: 6207650
    Abstract: Provided are very highly water soluble, stable, crystalline salts of 2′,3′-dideoxy-2′,3′-didehydrothymidine (“d4T”), 2′,3′-dideoxyinosine (“ddI”), and 2′,3′-dideoxy-2′-fluoroinosine (“F-ddI”). Such salts are useful as intermediates or as antiviral agents.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: March 27, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph B. Bogardus, Murray A. Kaplan, Robert K. Perrone
  • Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
    Patent number: 6194390
    Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: February 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Franco Lori, Andrea Cara, Wen-Yi Gao, Robert C. Gallo
  • Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2?,3?-dideoxy-uridines and their pharamaceutical compositions
    Patent number: 6191120
    Abstract: Contraceptive activity as well as anti-viral protection can be provided by contraceptive compositions containing a pyrimidine-based nucleoside or nucleotide exhibiting spermicidal or sperm-immobilizing activity. In one example, the active ingredient contains a thymine ring (e.g. AZT) that has 5-halo, 6-alkoxy substitution. Additional improvements in anti-HIV activity for certain AZT derivatives are seen by providing the pentose ring of AZT with aryl phosphate substitution.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: February 20, 2001
    Assignee: Wayne Hughes Institute
    Inventors: Osmond D'Cruz, Fatih M. Uckun, Taracad Venkatachalam
  • High affinity nucleic acid ligands containing modified nucleotides
    Patent number: 6184364
    Abstract: Nucleic acid ligands containing modified nucleotides are described as are methods for producing such oligonucleotides. Such ligands enrich the chemical diversity of the candidate mixture for the SELEX process. Specific examples are provided of nucleic acids containing nucleotides modified at the 2′- and 5-position. Specific 2-OH and 2′-NH2 modified RNA ligands to thrombin are described.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: February 6, 2001
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Wolfgang Pieken, Diane Tasset, Nebojsa Janjic, Larry Gold, Gary P Kirschenheuter